Alfasigma to acquire Galapagos’ Jyseleca business
This development is part of Galapagos’ strategy to transform into a new biotechnology enterprise with a robust research and development pipeline for treating disease immunology and oncology fields.
Biotechnology company PRISM BioLab has signed a target exclusive research and licensing agreement with Japan headquartered company ONO Pharmaceutical for jointly creating a development candidate for the latter’s oncology target.